STAT Plus: CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure
CytoDyn's CEO claimed success on an investor call — but his description of the data suggests the study didn't meet its primary goal.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario